YAP1 and cancer: Next, we tested if YAP1/TAZ were indeed bonafide downstream targets of the β1-integrin-FAK signaling by treating cancer cells with a FAK inhibitor, PF-228, to inhibit auto-phosphorylation of Tyrosine 397 of this kinase.